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1. Introduction
Osteolytic  bone  disease  in  multiple  myeloma  (MM)  is  a  common  event.  Already  at
diagnosis, approximately eighty percent of patients present with abnormal bone structure
[1;2].  During  disease  progression  a  large  proportion  of  patients  will  develop  ostelytic
lesions  [3].  MM bone disease  not  only  results  in  a  reduced quality  of  life  due  to  pain,
pathological  fractures,  or  symptomatic hypercalcaemia [4];  but may also be the  deciding
factor that determines if a patient requires anti-myeloma treatment or if a watch and wait
strategy can be applied [5]. In this chapter we will discuss the normal bone remodelling
process, and how it is affected in MM. During the last decades, increased knowledge about
bone  pathophysiology  in  general  has  led  to  an  improved  understanding  of  MM  bone
disease. The description of the receptor activator of nuclear factor kappa B (RANK) and
its ligand in the nineties was one of the most significant steps. We will also address how
biochemical markers may be used to monitor the velocity of the different processes in bone
remodelling. The next part of the chapter will be dedicated to the treatment of MM bone
disease. For many years, bisphosphonates have been a cornerstone in the treatment of MM
bone disease and despite the occurrence of osteonecrosis of the jaw that was first report‐
ed as a result of the of bisphosphonate treatment in the early part of this century, these
agents remain the most important components of treatment for MM bone disease. Lastly,
we will discuss how various anti-myeloma treatments may influence bone turnover. During
the last decade a number of novel drugs have been approved for the treatment of MM and
especially  proteasome  inhibitors  seems  to  have  a  positive  effect  on  MM  bone  disease
besides their anti-myleoma effect.
© 2013 Hinge et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Pathogenesis of multiple myeloma bone disease
2.1. Introduction
The reason for the excessive loss of bone mass observed in MM is multi factorial. For many
years attention was primarily focused on the increase in bone degradation which is observed
in the majority of MM patients.
Over the last decade however, it has become increasingly evident that impaired bone formation
also plays an important role in MM bone disease. In monoclonal gammopathy of unknown
significance (MGUS) and early stage MM with preserved bone structure, normal or even
increased bone formation may be observed. With disease progression and development of
osteolytic lesions bone formation becomes impaired, and this may be an important contribu‐
ting factor for the development of osteolytic lesions (see figure 1).
The interaction between the bone marrow microenvironment and the myeloma cells is also
considered to be crucial. A large number of cytokines and chemokines, that regulate the activity
of bone resorbing osteoclasts and bone forming osteoblasts, have been identified and studied in
MM. Recently, a structure consisting of a flat layer of osteoblast lineage cells, that separates the
bone surface from the bone marrow during bone remodelling, has been described. Disruption
of this cell layer, called the bone remodelling compartment (BRC) canopy, allows direct contact
between myeloma cells and the active bone remodelling cells, and this may affect both cell types.
Osteocytes have been sparsely investigated in MM. However, a recent article illustrates that also
this type of cell may be important for a better understanding of MM bone disease [6].
Bone resorption markers Bone formation markers 
With permission from the author; Søndergaard T. The effect of simvastatin on bone markers in multiple myeloma and
a description of the bone remodeling compartment. University of Southern Denmark, 2008.
Figure 1. Number of studies evaluating biochemical markers of bone turnover in MM patients in a ten year period.
Bone resorption markers are uniformly elevated, while the bone formation markers are more divergent, with in‐
creased levels observed in early stages of MM.
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3. Normal bone remodelling
Osteoclasts are the cells responsible for bone resorption. They originate from the monocyte-
macrophage cell line. Differentiation of hematopoietic precursor cells into mature osteoclasts
requires different environmental factors of which macrophage-colony stimulating factor (M-
CSF) and receptor activator for NF-κB ligand (RANKL) play an essential role. The early step
in osteoclastogenesis seems to be influenced by M-CSF [7], whereas RANKL initiates differ‐
entiation, cell fusion, and activation of mature osteoclasts [8]. During osteoclast development
the cell replaces the nonspecific esterase activity with tartrate-resistant acid phosphatase
isotype 5b (TRACP 5b), which is believed to be specific for osteoclasts. Osteoclastogenesis
results in the formation of large multinucleated cells located on the bone surface where bone
degradation takes place. Bone degradation is achieved by an active secretion of protons from
the osteoclasts into the resorption pits. The protons decrease the pH and cause decalcification
of the bone matrix [9]. After decalcification the collagen fibres are degraded mainly by the
proteolytic enzymes cathepsin K and various matrix metalloproteinases [10].
Osteoblasts are responsible for the formation of new bone following osteoclast-mediated bone
resorption. Osteoblasts originate from differentiated mesenchymal stem cells under the
influence of Runt-related transcription factor (Runx2) and the wingless type signalling (Wnt)
factors. Runx2 is required for the differentiation of mesenchymal cells into osteoblasts [11].
The Wnt-pathway mediates the formation of a complex, which in turn inhibits the proteasomal
degradation of β-catenin. The increasing level of β-catenin has a stimulating effect on osteoblast
differentiation and maturation [12]. The Wnt-pathway can be inhibited by Dickkopf 1 (DKK1),
resulting in decreased bone formation.
Mature osteoblasts are lined in groups located along the newly resorbed bone. Placed on the
resorption site, the osteoblasts secrete the components needed to generate bone matrix, mainly
collagen type 1 [13]. The bone formation ends with calcification of the newly synthesized bone.
During bone formation some osteoblasts are incorporated into the bone matrix and become
osteocytes. Bone lining cells and the canopy cells are also of osteoblast lineage.
Activation of bone remodelling is not yet clearly understood. However, it is thought that
osteocytes may, at least partly, be of importance for the activation of bone remodelling.
Osteocytes in the bone matrix may respond to mechanical stimulation and via communication
through their networks of canaliculli initiate bone resorption. Osteocyte death probably also
plays a role in the recruitment of osteoclasts.
Bone remodelling takes place on bone surface where the osteoclasts and osteoblasts are
covered by a canopy of flattened cells of osteoblast lineage [14;15]. The space between the
canopy and the bone surface undergoing remodelling is named the bone remodelling com‐
partment (BRC). Disruption of the BRC canopy may impair bone remodelling [16]. Several
factors of importance for the regulation of bone remodelling have been identified during the
last decades. Within this chapter, we will only review some of the most important. The RANKL,
RANK, and the decoy receptor osteoprotegerin (OPG) are probably the most significant factors
in the regulation of normal physiological bone remodelling. RANK is expressed on the surface
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of osteoclast precursor cells, and as mentioned above, stimulation with RANKL is essential for
osteoclastogenesis [17]. RANKL is expressed by osteoblasts and bone marrow stromal cells.
OPG has a high affinity for RANKL and functions as the physiological inhibitor of RANKL
[18]. Since osteoblasts can stimulate osteoclast activity through the expression of RANKL and
inhibit it through the secretion of OPG, osteoblasts hold a key position in the coupling between
bone formation and bone degradation. Another interesting regulator of bone degradation is
macrophage inflammatory protein 1-α (MIP-1α). MIP-1α has been shown to be a potent
activator of osteoclasts [19]. MIP-1α stimulates the activity and formation of osteoclasts
indirectly by increasing the stromal cell expression of RANKL on the one hand [20; 21], but it
also stimulates osteoclast formation independently of the RANKL system, though binding to
the CCR1 or the CCR5 osteoclast receptor [21].
Figure 2. Normal bone remodelling and bone remodelling in multiple myeloma. A: Osteocytes sense mechanical
stress and activate bone remodelling. B: Osteoclast precursors differentiate into mature multinucleated osteoclasts. C:
The osteoclasts resorb bone matrix. D: Following bone resorption mononucleated osteoblasts lay down new bone in
the resorbed area. E: During bone formation of new bone, osteoblasts are imbedded in the new bone matrix and dif‐
ferentiate into osteocytes. F: The bone remodelling takes place beneath a canopy of cells belonging to the osteoblast
lineage G: Malignant plasma cells disrupt the bone remodelling compartment canopy and H: Increase osteoclastogen‐
esis and I: Decrease osteoblastogenesis.
4. Abnormal bone remodelling in multiple myeloma
Increased bone degradation is an early event in MM. Retrospective studies using bone
histomorphometry on bone marrow biopsies from patients diagnosed with MGUS harvested
three to twelve months before these patients developed MM, were found to have increased
bone degradation compared with MGUS patients who did not progress to MM during the first
year after MGUS was diagnosed [22]. In MM both the number and the activity of the osteoclasts
are found to be increased, and this may result in either focal or more diffuse loss of bone matrix
when not compensated for by an equal increase in bone formation [23;24].
Several factors of importance for the development of MM bone disease have been identified
during the last decades. The RANK/RANKL/OPG system is one of the most significant. In
normal bone remodelling the RANKL/OPG ratio is tightly balanced. In MM the RANKL/OPG
ratio is increased, both due to an elevated level of RANKL and as a result of a decrease in the
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level of OPG, thus resulting in increased bone resorption [25]. The increased soluble RANKL/
OPG ratio has been shown to correlate with the extent of bone disease and even with overall
survival [25;26]. In addition, myeloma cells stimulate bone degradation by the secretion of
MIP-1α. In approximately 70% of MM patients, bone marrow serum levels of MIP-1α are
elevated [27] and peripheral blood levels of MIP-1α have been found to correlate with bone
disease and overall survival [28;29].
Vascular endothelial growth factor (VEGF) is known to be important for neovascularisation,
but it probably also plays a role in the activation of osteoclasts in MM. VEGF has been
demonstrated, in vitro, to act like macrophage colony-stimulating factor (M-CSF), thus
inducing osteoclast differentiation [30]. Furthermore, a simultaneous blockade of VEGF and
osteopontin has been shown to inhibit angiogenesis and bone resorption in co-cultures of
myeloma cells and osteoclasts [31]. Taken together, these results indicate that VEGF could be
of importance in bone resorption, and since the majority of myeloma cells can secrete VEGF it
has been suggested that VEGF may support osteoclastic bone resorption in MM [32]. Inter‐
leukin-6 (IL-6), stromal-derived factor-1α, tumor necrosis factor-α, and interleukin-11 are other
examples of cytokines known to stimulate osteoclasts, which are suggested to be of importance
in the development of MM bone disease [33;34].
The myeloma cells do not only affect the osteoclasts indirectly through the secretion of
cytokines into the bone marrow microenvironment, but a direct contact between myeloma
cells and bone marrow stromal cells or osteoclasts also seems to be an important factor in the
development of MM bone disease.
Disruption of the BRC canopy is a frequent finding in MM. This breakdown of the BRC canopy
allows a direct contact between the myeloma cells and the osteoclasts and osteoblasts involved
in bone remodelling. This event probably contributes to impaired bone formation and
enhanced bone resorption [16]. The extent of BRC canopy disruption in a histomorphometric
study of iliac crest biopsies was found to correlate with the magnitude of osteolytic lesions in
patients with MM [16]. Direct contact between human myeloma cells and bone marrow stromal
cells or pre-osteoblasts tested in a co-culture system resulted in a marked decrease in the
production of OPG, and thereby an imbalance in the RANKL/OPG ratio resulting in increased
bone degradation [35]. Cell to cell contact between myeloma cells and bone marrow stromal
cells has also been demonstrated to induce the secretion of IL-6 by bone marrow stromal cells
[31]. IL- 6 stimulates osteoclast formation and also has a promoting effect on myeloma cell
proliferation [36]. It has also been suggested that myeloma cells can fuse with osteoclasts to
create myeloma-osteoclast hybrid cells that may more aggressively erode bone than non-
hybrid osteoclasts [16;37].
Co-cultures of myeloma cells and osteoclasts have demonstrated an increased viability of the
myeloma cells caused by the direct cell to cell contact with osteoclasts [38]. Osteoclasts also
produce factors capable of promoting myeloma cell growth, including IL-6 [39] and insulin-
like-growth factor-1 (IGF-1) [40]. Osteoclasts can also support myeloma cell growth through
the production of angiogenic factors, and the direct contact between myeloma cells and
osteoclasts in co-cultures has been shown to enhance vascular tubule formation [41]. In animal
models the inhibition of osteoclast activity with recombinant OPG or bisphosphonates has
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resulted in an increased in survival of mice inoculated with myeloma cells [42;43] but the
clinical data from myeloma patients treated with bisphosphonates have been less consistent
[44-48]. Nevertheless, the existence of a vicious cycle of bone resorption and tumour growth
in patients with MM seems plausible and may be supported by the demonstration of a survival
advantage in patients treated with zoledronic acid in the MRC IX trial [49].
Bone disease in MM is not only caused by an increased bone resorption, but the formation of
new bone may also be affected. A reduced recruitment of osteoblasts, as well as reduced
mineral deposition has been observed using histological methods in patients with MM [22].
In early stage of MM the number and activity of the osteoblasts can be increased but a marked
decrease occurs as the plasma cell infiltration progresses [50]. Disruption of the BRC canopy
in MM may be an important cause of the uncoupling of bone resorption and bone formation,
with the result that bone resorption is not followed by bone formation or that the bone
formation process is delayed or abolished [16]. Human plasma cells purified from bone
marrow biopsies of MM patients have been found to express the gene for DKK1, and immu‐
nohistochemical analysis of bone marrow biopsies have shown that myeloma cells contain
DKK1 [51]. In addition, blood and bone marrow serum levels of DKK1 have been demonstrated
to be elevated in patients with MM bone disease [51]. Since DKK1 is believed to inhibit the
stimulation of osteoblastogenesis via the Wnt-pathway this might cause impaired bone
formation. Runx2 may also be affected by myeloma cells. Runx2 is required for osteoblast
differentiation. The expression of Runx2 by mesenchymal cells has been found to decrease
after direct cell to cell contact with myeloma cells in co-cultures [52].
Osteocytes have not been widely investigated, and their involvement in MM bone disease is
unknown. Histological examination of compact bone from MM patients shows a significant
change in the morphology of osteocytes and their lacunae [53]. Likewise, a major change in
the gene expression profile of osteocytes in MM has also been observed. This indicates that
osteocytes are markedly affected in MM. A recently published study showed that MM patients
had significantly smaller numbers of viable osteocytes compared to healthy individuals [6].
Likewise MM patients with bone lesions were found to have a smaller number of viable
osteocytes compared with MM patients without bone lesions. The amount of viable osteocytes
was found to be negatively correlated with the number of osteoclasts and the authors suggest
an involvement of the osteocytes in MM-induced osteoclast formation [6].
Futhermore, healing of bone lesions in MM bone disease does not occur frequently, even in
patients who respond well to anti-myeloma treatment. It remains unclear why bone remod‐
elling does not normalise when the influence from myeloma cells disappears after successful
treatment. It may be due to irreversible damage of key elements in the bone formation process
(i.e. the BRC).
5. Biochemical markers of bone turnover
Conventional radiography has for many years been the standard method for the diagnosis of
myeloma bone disease. This modality, however, suffers from a low sensitivity, since 30% of the
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trabecular bone mass must be absent for a lesion to become detectable. Computed tomogra‐
phy can increase the sensitivity at the cost of higher radiation exposure. Both modalities, however,
only provide static information concerning the accumulated bone disease. Biochemical markers
of bone turnover can provide dynamic information concerning the velocity of bone turn-over at
any given time point, and can be measured from either blood or urine samples. Furthermore,
bone formation and bone resorption can be evaluated separately. Bone markers can be divid‐
ed into two categories: they are either collagen fragments released during the formation or
destruction of the collagen triple helix structure of which bone consists, or they are enzymes
released form either osteoblasts or the osteoclasts (see figure 3). Bone resorption markers from
the first group include the cross-linked telopeptides of type-1 collagen NTX, CTX, ICTP and DPD
(Table 1). They are products of osteoclast-mediated degradation of collagen and therefore reflect
bone resorption. Bone formation markers from this group include PINP and PINC (Table 1).
These markers are products of the cleavage process of procollagen into collagen and therefore
the measured levels will reflect the amount of newly formed bone matrix. The second group of
bone markers include TRACP-5b, bALP and OC (Table 1). TRACP-5b is secreted by osteo‐
clasts and used as a marker of osteoclast number and activity, whereas bALP and osteocalcin
are produced by osteoblasts and used as markers of osteoblast number and activity. The levels
of bone markers have been shown to correlate with the degree of bone resorption or bone
formation  using  classical  bone  histomorphometry  [54;55].  Furthermore,  bone  resorption
markers decrease when treatment with anti-resorptive drugs is initiated [56]. Conversely, the
discontinuation of anti-resorptive drugs leads to a rise in bone resorption markers [57]. However,
when using biochemical markers it is important to be aware of the fact that the level of mark‐
ers may be influenced by a number of factors, such as age, gender, drugs, renal- and liver function
or diet. Especially the collagen-mediated markers are sensitive to food intake. Despite the interest
in bone markers, there is still no consensus on how they should be used to monitor disease activity
and response to treatment in MM [58].
Bone marker Abbreviation Type Analytical specimen
C-terminal cross-linking telopeptide
of type-1 collagen CTX Bone resorption marker Serum, Urine
N-terminal cross-linking telopeptide
of type-1 collagen NTX Bone resorption marker Serum, Urine
C-terminal cross-linking telopeptide
of type-1 collagen generated by
metalloproteinase
ICTP Bone resorption marker Serum
Deoxypyridinoline DPD Bone resorption marker Serum, Urine
Tartrate-resistant acid phosphatase
isotype 5b TRACP-5b
Bone resorption marker
osteoclast activity Serum
Bone-specific alkaline phosphatase bALP Bone formation marker Serum
Osteocalcin OC Bone formation marker Serum
Procollagen type-1 N-propeptide PINP Bone formation marker Serum
Procollagen type-1 C-propeptide PICP Bone formation marker Serum
Table 1. Biochemical markers of bone turnover
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6. Treatment of multiple myeloma bone disease
6.1. Anti-resorptive treatments:
Until now, bisphosphonates remain the only registered agents for the treatment of osteolytic
bone disease in MM. Bisphosphonates are synthetic analogues of pyrophosphate with a high
affinity for the hydroxyapatite in the bone. After administration, bisphosphonates are rapidly
cleared from the blood and incorporated into the bone matrix or excreted through the kidneys.
If imbedded in the bone matrix they remain incorporated for many years, or until the bone is
degraded by the osteoclasts [59]. Three generations of bisphosphonates exist, and each is many
fold more potent than the previous [60]. The different bisphosphonates can be distinguished
by the absence or presences of a nitrogen atom in the R2 position of the bisphosphonate, with
the amino-bisphosphonates being the most potent. When the osteoclast degrades bone, the
bisphosphonate is taken up through endocytosis and causes apoptosis either through the
incorporation into non-functional adenosine triphosphate (non-nitrogen containing bi‐
sphosphonates), or through the inhibition of farnesyl pyrophosphate synthase (nitrogen
containing bisphosphonates)[61]. Early studies, using the least potent bisphosphonate,
etidronate, showed no clinical benefit on MM bone disease [62], whereas the slightly more
potent clodronate could diminish progression of osteolysis, but had no effect on bone pain or
collagen breakdown 
osteoclast cell  
                procollagen 
NTX, CTX, ICTP, DPD PINP, PICP 
BONE RESORPTION BONE FORMATION 
osteoblast cell  
TRACP5b  bALP  
OC 
Figure 3. Biochemical markers of bone remodelling can be divided into markers reflecting bone resorption (left) and
marker reflecting bone formation (right). They can also be divided in markers reflecting a change in the collagen ma‐
trix (upper part) or markers reflecting the activity of bone resorbing or bone forming cells (lower part).
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pathological fractures [63]. In 1996 and 1998, Berenson et al. published two studies, in which
patients were randomised to placebo or the amino-bisphosphonate pamidronate. A significant
effect was observed with regard to reduced pain, fewer skeletal related events, and improved
quality of life [64;65]. Initially, no effect could be observed in overall survival, however using
a Cox multivariable regression analysis a slight increase in overall survival was observed for
a subgroup of patients. A subsequent phase III trial, comparing the more potent bisphonate
zoledronic acid with pamidronate in breast cancer patients with bone metastases and MM
patients, demonstrated a superiority of zoledronic acid over pamidronate in reducing skeletal
events in the breast cancer group but not in the MM sub-population. No difference was
observed in overall survival [66]. Later publications indicated that there could be an effect on
overall survival but only with the most potent bisphosphonates [67-70]. In 2010 a large meta-
analysis concluded that there was no effect on overall survival in MM provided by bisphosph‐
onates in general [71]. However, later the same year the large MRC IX trial, reported that
zoledronic acid was superior to the non-nitrogen containing bisphosphonate clodronate, not
only with regard to the control of bone disease, but zoledronic acid also increased overall
survival by 5.5 months [49]. Because of the MRC IX data, an updated version of the meta-
analysis was published in 2012. Still, no significant effect on overall survival was observed for
bisphosphonates in general, but “meta regression analysis indicated that the beneficial effect
of bisphosphonates on mortality in patients with MM may be a function of drug potency, with
zoledronate being the most potent” [72].
Bisphosphonates are potential nephrotoxic compounds and dosage adjustment according to
creatinine clearance are required [73].
In 2003, it was reported for the first time, that exposure to bisphosphonates could also cause
osteonecrotic lesions, especially in the oral cavity. This complication was termed bisphosph‐
onate-associated osteonecrosis of the jaw (BON) [74]. BON is commonly observed after surgical
dental procedures, e.g. tooth extractions, but spontaneous cases do occur [75]. The incidence
of BON increases with treatment duration [76], as well as with the potency of the bisphosph‐
onate used [77]. The aetiology of BON remains controversial. One possible explanation could
be that the profound suppression of osteoclast activity results in the accumulation of micro‐
fractures in the bone. This explanation is in accordance with the fact that BON incidence
increases with treatment duration and potency of bisphosphonate type and that BON is also
observed after treatment with denosumab, a monoclonal antibody that inhibits osteoclast
activity by binding to RANKL. It has also been suggested that BON may occur because of the
anti-angiogenic effects of bisphosphonates [78]. Indeed, BON seems to be more commonly
observed in patients receiving other anti-angiogentic compounds such as thalidomide [77].
Thirdly, it has been speculated that the frequent findings of actinomycosis in the lesions may
be part of the pathogenesis and not only a secondary event, especially since prophylactic
antibiotics during dental procedures seem to reduce the incidence of BON [79]. Recently,
osteomalacia, which in adults is often a consequence of vitamin D deficiency, has been
suggested as a risk factor for BON [80]. Once established BON is difficult to cure, and surgical
treatment may worsen the situation [75]. Case-reports suggest several treatment modalities,
including low-level laser therapy [81;82], hyperbaric oxygen treatment [83], long-term
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administration of antibiotics [84], autologous bone marrow transplantation [85], and ozone
therapy [86]. Because of the difficulties in treating BON, focus has mainly been on preventing
the occurrence in the first place. This has been done partly by implementing preventive dental
procedures prior to the initiation of therapy with bisphosphonates, but probably more
importantly by reducing the exposure time to bisphosphonates. The oral microflora also seems
to play a role in the development of BON and antibiotic prophylaxis before dental procedure
may reduce the risk of developing BON [79]. Concerning the preventive procedures, there are
data indicating a positive effect [87;88]. Concerning the reduced exposure time there are few
supportive data, but recommendations based on expert opinion do exist [89-92]. Corso et al.
demonstrated that monthly infusions for one year followed by four infusions the following
year offered equal bone protection but reduced BON incidence compared to the monthly
infusions for two years [93]. Lund et al. have provided evidence that one year of monthly
infusions offers inferior anti-resorptive protection after discontinuation compared with two
years of monthly infusions based on consecutive measurement of markers of bone turnover
[57]. A more rational approach to reduce the bisphosphonate load without increasing the risk
of osteolysis, could be to monitor the patient´s ongoing bone remodelling using biochemical
markers of bone turnover in order to provide individualized treatment. Data now exist which
indicate that bone remodelling markers may predict osteolysis before it becomes manifest by
X-ray or CT-scan [94].
Denosumab is a humanized antibody with high affinity for RANKL. By targeting RANKL,
denosumab mimics physiological OPG and thus blocks the stimulation of the osteoclasts
through the NF-κB receptor. Denosumab could be expected to have a favourable impact on
MM bone disease due to its effect on the increased RANKL/OPG ratio observed in MM
patients. In 2006 Body et al. published a study investigating the effect of a single dose of
subcutaneous denosumab compared with a single dose of intravenous pamidronate on the
urinary and serum levels of the bone resorption marker NTX. The study population consisted
of 54 patients with bone lesions and either MM (n=25) or breast cancer (n=29). The study
reported that the compounds were well-tolerated and to a similar extent decreased the
investigated bone resorption marker NTX [95]. A phase II study including 96 MM patients, in
either relapse or plateau phase, where denosumab was administered every fourth week also
demonstrated a decrease in bone resorption markers, even in patients previously treated with
bisphosphonates, with an acceptable safety profile [96]. In a phase III trial patients (n=1776)
with cancer bone metastases (excluding breast and prostate cancer) or MM (10% of the study
population) were randomized to treatment with either zoledronic acid or denosumab.
Denosumab was found to be equivalent to zoledronic acid in delaying time to first on-study
skeletalrelated event. Noteworthy, in a subgroup analysis of the MM patients (n=180),
mortality appeared to be increased in those treated with denosumab with a hazard ratio of
2.26 (95% CI: 1.13-4.50) [97]. Recently, new data from this trial has been published. Results of
patient-reported outcomes of pain and health-related quality of life were reported to be equal
in the two treatments arms [98]. The frequency of osteonecrosis of the jaw seemed to be equal
for treatment with denosumab or zoledronic acid [97;99]. Denosumab is currently not regis‐
tered for the treatment of MM bone disease by US Food and Drug Administration or the
European Medicines Agency. [100;101], but it could perhaps in the future be used for the
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treatment of bone disease in patients with renal failure who are not suitable for treatment with
bisphosphonates due to the risk of aggravation of renal function.
6.2. Possible future anti-resorptive drug treatments
Several drugs targeting MM bone disease are under development e.g. the CCR1-inhibitor
(MLN3897) that blocks the CCR1 receptor on osteoclasts and thereby prevents stimulation by
MIP-1α [102]. Another candidate for the treatment of MM bone disease is the anti-DKK1
human antibody BHQ880. The agent has been shown to increase osteoblast differentiation in
vivo and in animal models to significantly increase the number of osteoblasts and trabecular
thickness [103]. Whether this bone anabolic effect will be found in humans will be of interest
because it raises the possibility for not only preventing bone loss, but also supporting new
bone formation. Clinical trials with BHQ880 are ongoing [104].
6.3. Anti-myeloma treatments
Treatment of MM using conventional chemotherapy usually does not induce healing of
osteolytic lesions even if patients respond well to the anti-myeloma treatment and obtain long
progression free periods [105-107]. Although markers of bone resorption may decrease [55]
serum levels of bone formation markers remain suppressed as a sign of continuously impaired
bone formation even in patients who have obtained complete response after treatment with
conventional chemotherapy [56;108].
Proteasome inhibitors have a well-documented anti-myeloma effect and they may also have
an impact on MM bone disease through the inhibition of osteoclasts and stimulation of
osteoblasts.
In vitro studies have demonstrated that proteasome inhibitors inhibit osteoclast differentiation
and resorptive activity by reducing the activity of NF-κB [109;110]. In vivo studies of the effect
of bortezomib on bone resorption markers show a rapid and significant decrease in CTX and
urinary NTX, but it has also been observed that the levels begin to increase again already 2-3
days after the intravenous injection of bortezomib [111]. The levels of the bone resorption
markers CTX and TRACP-5b and the RANKL/OPG ratio were also found to decrease after
four cycles of treatment with bortezomib in a clinical study including 34 myeloma patients
[112]. The ubiquitin-proteolytic pathway is a regulator of bone formation [113] and by blocking
this pathway proteasome inhibitors can stimulate osteoblast differentiation. Suggestions of the
underlying mechanism have been that proteasome inhibitors may increase the level of bone
morphogenetic protein 2 [114] and prevent the proteolytic degradation of RUNX-2 [115]. In
an in vitro study, it has been suggested the bortezomib may enhance bone formation through
the inhibition of DKK1 expression in osteogenic cells [116]. More studies have provided
evidence that proteasome inhibitors stimulate osteoblasts and bone formation in vitro as well
as in animals models [114;116-118], and histological investigations have demonstrated
increased numbers of osteoblasts in bone marrow sections from MM patient treated with
bortezomib [115]. Clinical studies have demonstrated that anti-myeloma treatment with
bortezomib induces an increased level of biochemical markers of bone formation both with
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regard to markers of osteoblast activation and also bone matrix deposition [118;119]. Alkaline
phosphatase was found to be significantly increased in patients who responded to bortezomib
treatment [119]. In another clinical study bone-specific alkaline phophatase (bALP) and
osteocalcin were found to be increased not only in responding patients, but also in patients
who did not achieve an anti-myeloma response to treatment with bortezomib [120]. This result
supports the assumption that bortezomib may have a bone anabolic effect independent of its
anti-myeloma effect. Enhancement of bone matrix deposition after mono-therapy with
bortezomib, has also been shown by the demonstration of increased serum levels of PINP
(Procollagen Type-I N-terminal propeptide) [118]. Both bALP and osteocalcin were found to
be increased after treatment with bortezomib in a clinical study of 34 relapsed myeloma
patients in non-responders and responders but the increase was highest in responding
patients. However no radiographic signs of healing of the baseline osteolytic lesions were
observed six month post-treatment [112]. Radiologic evidence of healing of lytic lesions was
observed in six out of 11 patients who responded to combination treatment with bortezomib,
melphalan, and prednisone while none of the evaluated patients who had achieved a response
to treatment with melphalan and prednisone without bortezomib showed radiological signs
of healing [121].
Pomalidomide (originally CC-4047), is a derivative of thalidomide that is anti-angiogenic and
acts as an immunomodulator. Pomalidomide is now tested in Phase III clinical trials and will
hopefully soon become available treatment of patients with relapsed or refractory MM. The
drug has been granted orphan status for the treatment of MM by the European Medicines
Agency [122]. Pomalidomide has been shown to inhibit osteoclasts differentiation in bone
marrow cultures which leads to a strong inhibition of bone resorption [123]. The inhibition of
osteoclast formation seems to occur through a reduction of the PU.1 expression. PU.1 is a
critical transcription factor in the development of mature osteoclasts. Lenalidomide, another
thalidomide derivative, has been shown to inhibit both an early step in osteoclastogenesis
through reduction of PU.1 expression and to reduce secretion of RANKL from bone marrow
stroma cells derived from patients with MM [124]. In a clinical study including 20 MM patients
with bone disease Breitkreuts et al. found a significant decrease in the serum levels of the
RANKL/OPG ratio after two cycles of treatment with lenalidomide [124]. Likewise, treatment
with thalidomide in combination with dexamethasone has a favourable effect on the RANKL/
OPG ratio [125]. Treatment with thalidomide in combination with dexamethasone can also
decrease the levels of the bone resorption markers CTX, NTX and TRACP-5b, however the
treatment does not increase the bone formation marker bALP or osteocalcin [126]. The failure
to increase bone formations markers in serum, correlates with the observation that none of the
responding patients in a clinical study of patients treated with a thalidomide/dexamethasone
combination, showed any radiological signs of healing of osteolytic lesions [125].
7. Conclusion
The pathophysiology in multiple myeloma bone disease is complex. There is evidence that not
only osteoclast activity but also other cells and structures responsible for normal bone
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metabolism are affected in different ways, suggesting that different targets for treatment may
be identified. The notion that myeloma-induced stimulation of osteoclast may promote growth
of myeloma cells and thus create a vicious circle emphasise the importance of improved
understanding as well as development of more efficient treatment of myeloma-induced bone
disease. Bisphosphonates remain so far the only registered drugs for treatment of multiple
myeloma bone disease. Due to risk of renal damage and bisphosphonate-associated osteonec‐
rosis of the jaw after treatment with the potent amino-bisphosphonates, alternatives are
wanted and several new drugs are under investigation. Furthermore, the optimal duration of
treatment with bisphosphonates remains unknown.
Treatment with conventional chemotherapy does not induce healing of osteolytic lesion even
in patients who have obtained complete response. However, novel drugs used for treatment
of multiple myeloma seem to affect bone metabolism besides their anti-myeloma effect and
cases with radiological signs of healing following treatment with bortezomib have been
reported.
The last decade has brought the understanding of multiple myeloma bone disease to a higher
level, new anti-myeloma drugs with positive effect on bone disease have been registered and
more are undergoing investigation. Still many questions regarding the pathophysiology and
treatment of multiple myeloma bone disease remain to be answered.
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